- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05940493
Abemaciclib in Newly Diagnosed Meningioma Patients
A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.
Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy.
This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ivy Research Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- St. Joseph's Hospital and Medical Center
-
Contact:
- Navigator
- Phone Number: 602-406-8605
- Email: research@ivybraintumorcenter.org
-
Principal Investigator:
- Nader Sanai, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant with an intracranial WHO Grade 3 meningioma or lower grade meningioma that has progressed to WHO grade 3 that have received prior radiation therapy.
- Resected tissue must demonstrate: (a) RB positivity on immunohistochemistry (IHC); or, no RB mutations on next-generation sequencing (NGS).
- A washout period of 14 to 35 days is required between end of RT and Day 1 and must be fully recovered from the acute effects of RT.
- Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).
- Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Participant must be willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
- Age ≥18 years at time of consent.
- Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale.
- Ability to swallow oral medications.
- Participant has adequate bone marrow and organ function
- Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.
- For females of reproductive potential: use of highly effective contraception during study participation and for an additional 3 weeks after the end of treatment administration.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 3 weeks after the end of treatment administration.
Exclusion Criteria:
- Prior history of cancer with ongoing treatment of disease.
- Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
- Pregnancy, breastfeeding or lactation.
- Known allergic reactions to components of the abemaciclib.
- Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1.
- Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis.
- Known active systemic bacterial infection, fungal infection, or detectable viral infection .
- Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
- Prior therapy with any CDK4/6 inhibitor.
- Treatment with another investigational drug within 5 half-lives of the investigational product.
- The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Treatment (Abemaciclib)
Administered twice daily on days 1-28 of each 28-day cycle.
|
Tablet
|
Placebo Comparator: Placebo
Administered twice daily on days 1-28 of each 28-day cycle.
|
Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: 24 months
|
Progression free survival (PFS24) rate measured from the time of surgery to date of recurrence
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deaths
Time Frame: 24 months
|
Number and incidence of deaths
|
24 months
|
Drug-related toxicity
Time Frame: Up to 30 days after last study dose
|
Incidence of drug-related toxicity
|
Up to 30 days after last study dose
|
Adverse Events
Time Frame: Up to 30 days after last study dose
|
Number of adverse events through study completion
|
Up to 30 days after last study dose
|
Incidence of clinical laboratory abnormalities per CTCAE
Time Frame: Up to 30 days after last study dose
|
Clinical laboratory abnormalities per CTCAE
|
Up to 30 days after last study dose
|
Progression-free survival in participants
Time Frame: 12 months
|
12 month progression-free survival (PFS12) rate measured from the time of surgery to date of recurrence.
|
12 months
|
Overall Survival
Time Frame: 24 months
|
Overall survival at 24 months
|
24 months
|
Median Overall Survival
Time Frame: 5 years
|
Median overall survival
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nader Sanai, MD, Ivy Brain Tumor Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-14
- 23-500-352-34-38 (Other Identifier: St. Joseph's Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningioma
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
Northwestern UniversityNational Cancer Institute (NCI); NovoCure Ltd.RecruitingAtypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
Nancy Ann Oberheim Bush, MDMerck Sharp & Dohme LLCRecruitingRecurrent Meningioma | Grade I Meningioma, Adult | Grade II Meningioma, Adult | Grade III Meningioma, AdultUnited States
-
National Cancer Institute (NCI)RecruitingGrade 2 Meningioma | Grade 3 Meningioma | Recurrent MeningiomaUnited States
-
University of NebraskaChimerixNot yet recruitingMeningioma | Refractory Meningioma | Relapsed MeningiomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingIntracranial Meningioma | Grade II MeningiomaCanada, United States, Japan, Saudi Arabia, India
-
Ohio State UniversityRecruitingCognitive Impairment | Cognitive Decline | Meningioma | Skull Base Meningioma | Frontal Meningioma | Temporal Meningioma | Post-Surgical CognitionUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMeningioma | Anaplastic Meningioma | Meningioma AtypicalItaly
-
National Cancer Institute (NCI)CompletedRecurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Meningioma | Adult Grade III MeningiomaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States